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Abstract
Introduction
Hypertension is a leading cause of stroke, coronary
artery disease, heart attack, and heart and kidney fail-
ure in the United States, all of which contribute to the
rising costs of health care. The Georgia Stroke and Heart
Attack Prevention Program is an education and direct
service program for low-income patients with hyperten-
sion. This project evaluated the cost-effectiveness of the
program compared with the following two alternative
scenarios: no treatment for high blood pressure and the
typical hypertension treatment received in the private
sector nationwide (usual care).
Methods
We estimated the preventive treatment costs and num-
ber of adverse health events averted (hemorrhagic and
ischemic stroke, heart disease, and kidney failure) associ-
ated with the Georgia Stroke and Heart Attack Prevention
Program in two Georgia health districts. We used program
cost and service usage data obtained from the Georgia
Department of Human Resources and probabilities and
costs of expected adverse events published in peer-
reviewed sources. We compared program costs and num-
ber of expected adverse health events averted with those
expected from 1) no preventive care and 2) usual care for
high blood pressure.
Results
The Georgia Stroke and Heart Attack Prevention
Program was less costly and resulted in better health out-
comes than either no preventive care or usual care.
Compared with no preventive care in the two districts, the
program was estimated to result in 54% fewer expected
adverse events; compared with usual care, the program
was estimated to result in 46% fewer expected adverse
events. Combining the costs of preventive treatment with
the costs of expected adverse events, the Georgia Stroke
and Heart Attack Prevention Program cost an average of
$486 per patient annually, compared with average annual
costs of $534 for no care and $624 for usual care.
Conclusion
Maintaining a publicly financed stroke and heart
attack prevention program is more cost-effective and
results in greater health benefits than other plausible
scenarios. Because the benefits of this program accrue to
both the state and federal governments through reduced
Medicaid and indigent care expenditures, both the state
and federal governments have a financial incentive to
support the program.
Introduction
Hypertension is a leading cause of stroke, coronary
artery disease, heart attack, and heart and kidney failure
in the United States. Currently, 50 million Americans
have hypertension and another 45 million have prehy-
pertension (blood pressure of 120–139 mm Hg [systolic]
or 80–89 mm Hg [diastolic]) (1). More than 70% of U.S.
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adults with hypertension do not have it under control
(2,3). Hypertension is particularly common among
African Americans, who have a 30% higher prevalence of
hypertension than whites (1). As might be expected,
African Americans experience hypertension-related
deaths at younger ages than whites and have higher
rates of stroke, left ventricular hypertrophy, and heart
attack (3). Some but not all of these differences are
explained by the lower socioeconomic status (SES) of
African Americans, because lower SES is also strongly
related to uncontrolled blood pressure (4). As many as
30% of all deaths among African American men and 20%
of all deaths among African American women can be
attributed to high blood pressure (5).
Aggressive treatment of hypertension, which usually
involves medication, significantly decreases the risk of
coronary artery disease, congestive heart failure, stroke,
and resulting disability. For example, a 12-point to 13-
point reduction in blood pressure can lower the risk of
heart attack by 21%, stroke by 37%, and total cardiovascu-
lar deaths by 25% (6). Results of recent large hypertension
trials demonstrated that inexpensive thiazide-type diuret-
ics are superior in preventing one or more major forms of
cardiovascular disease (7). Unfortunately, low-income indi-
viduals without prescription drug coverage are significant-
ly more likely to skip doses to save money or make their
hypertension medication prescriptions last longer. In one
recently observed population, systemic hypertension was
adequately controlled among only 38% of those who paid
for their medication themselves (8).
The Georgia Stroke and Heart Attack Prevention
Program (SHAPP) is an education and direct service pro-
gram for low-income patients with hypertension. The
program is based on the Chronic Care Model, a frame-
work for identifying the essential elements of a health
care system and involving patients in their own care (9).
SHAPP patient services are provided through the coun-
ty health departments and include screening, referral to
physicians, diagnosis, and treatment. Treatment proto-
cols are based on Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure recommendations (10). Individual
patients are assigned to nurses who act as case man-
agers. SHAPP nurses then coordinate the wide array of
treatment services including physical and family history
assessments, diagnostic testing, lifestyle counseling and
education, medication, and patient monitoring (follow-
up visits for medication, blood pressure assessment, and
any needed testing) as stipulated by the SHAPP proto-
col. Information on patient medical and family history,
physical characteristics, and risk factors is collected.
Diagnostic testing is done to determine baseline and fol-
low-up blood pressure levels. Lifestyle counseling
includes advice on diet, weight, smoking cessation, alco-
hol consumption, and physical activity and information
about signs and symptoms of stroke and heart attack.
Nurses track medication side effects and monitor
patients to ensure they keep clinic appointments and
adhere to medication schedules. SHAPP also supplies
prescription drugs at low or no cost according to a treat-
ment protocol.
According to the Centers for Disease Control and
Prevention’s (CDC’s) Behavioral Risk Factor Surveillance
System (BRFSS), 1.7 million Georgians had hypertension
in 2004. Of those, 469,800 were low income, uninsured, or
underinsured and were potentially eligible for the SHAPP
program. (Eligibility is based on both income and hyper-
tension severity.) However, given the small enrollment in
SHAPP (15,819 clients in fiscal year 2003), there is likely
a much a greater need in Georgia for SHAPP services than
the program is currently able to meet.
Reducing hypertension can lead to marked reductions
(10) in the risk of several high-consequence adverse
events such as hemorrhagic stroke (11), ischemic stroke,
heart disease (12), and kidney failure (13). However, one
recent study suggests that less intensive interventions
that rely only on patients to manage their own hyperten-
sion care are relatively ineffective (14). Comparatively,
SHAPP is a higher-intensity intervention guided by the
premise that providing low-cost preventive services to
medically indigent patients provides benefits to patients
and savings to the state. SHAPP patients who control
their blood pressure could reduce their risks for adverse
events, thus prolonging and improving the quality of their
lives and lowering the annual medical costs borne by the
state for high-cost hospital care and procedures. Although
advocates of SHAPP have long suspected that the pro-
gram results in cost savings, the association among
SHAPP services, patient outcomes, and medical costs has
never been formally evaluated. In this article, we discuss
a limited, first-time evaluation of the costs and benefits of
SHAPP to determine whether this promising practice
results in enhanced patient health and reduced medical
costs for the state.
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Methods
Selection of districts
We collected administrative data on the costs and hyper-
tension control outcomes of SHAPP in two Georgia health
districts with high rates of blood pressure control for fiscal
year 2003 (July 1, 2002–June 30, 2003). Blood pressure
control is defined by the Georgia Department of Human
Resources (DHR) as a reading of less than 140/90 mm Hg,
based on the average of at least two blood pressure read-
ings taken on the most recent visit.
The selection and number of the districts studied was
guided by several factors. The primary goal of the study
was to examine the critical components of SHAPP in sites
with high success rates so that lessons could be shared
with other hypertension control programs. In addition to
analyzing costs, the full study included focus groups with
patients, interviews with clinic and administrative staff,
and an examination of the medical records. Time and fund-
ing limitations allowed for only two districts to be studied.
The two districts were selected based on their success in
controlling hypertension, use of different computer sys-
tems, geographic diversity between districts, demographic
diversity among counties within the districts, and the mix
of patients managed solely by the health department with
patients managed jointly by the health department and
private physicians. Although the characteristics of SHAPP
districts and clinics vary widely, the intention is for
SHAPP to perform at the same level in all districts. This
analysis represents the upper boundary of the potential
effectiveness of the SHAPP program.
Impact of SHAPP compared with plausible alternatives
After examining administrative data for each district, we
extrapolated the number of adverse health events — hem-
orrhagic stroke (11), ischemic stroke, heart disease (12),
and kidney failure (13) — that would be expected given the
level of blood pressure control within each district, and we
assigned costs to these events. We then compared cost and
health outcomes of SHAPP with two simulated plausible
alternatives: 1) no care and 2) the typical treatment
received in the private sector nationally (referred to as
usual care). We chose no care to represent the lower bound-
ary that Georgia’s SHAPP patients would receive in the
absence of the program, and we chose usual care to repre-
sent the upper boundary. If SHAPP were eliminated, its
patients could be expected to receive no care (the worst-
case scenario) or usual care (the best-case scenario).
Patients who received no care would be expected to have
no costs related to blood pressure control, but they would
also be expected to have a higher number of adverse
events. Our analysis evaluated whether the number of
expected adverse events prevented by SHAPP was suffi-
cient to justify the additional cost of SHAPP preventive
treatment.
Next, we compared SHAPP patients with a scenario in
which patients who had characteristics identical to
SHAPP patients received usual care. SHAPP patients and
patients who received usual care would be expected to dif-
fer in the following ways: 1) cost of treatment, 2) level of
hypertension control outcomes, and 3) the probability of
receiving treatment. Nationally, only 58% of people with
hypertension receive any regular preventive care, com-
pared with 100% of SHAPP patients, assuming SHAPP
patients seek care and are eligible for the program (1). This
analysis evaluated whether SHAPP resulted in less costly
treatment as well as fewer expected adverse health events
than usual care. Advocates have suggested that SHAPP is
both less expensive for and more effective at controlling
blood pressure than care provided in private settings
because SHAPP uses evidence-based protocols whereas
private providers may substitute alternative protocols;
SHAPP uses fewer new, more costly (and not necessarily
more effective) prescription drugs; and SHAPP substitutes
nurse practitioners for physicians to manage patient care.
SHAPP could be more beneficial than usual care by offer-
ing full coverage to all patients who are eligible and seek
treatment, by providing services at lower costs, or by
achieving better outcomes.
SHAPP data and costs
We examined typical direct and indirect SHAPP pro-
gram costs using methodology recommended by the
National Panel on Cost-Effectiveness Analysis in Health
and Medicine convened by the U.S. Public Health
Service (15). Total program costs include the cost of serv-
ices (e.g., diagnostic testing, patient visits), medications,
and overhead costs. Overhead costs include personnel
costs (e.g., salary, benefits) and operating costs (e.g.,
pharmacy, clinical). Total annual SHAPP clinical costs
were supplied for two selected counties in District 1 and
District 2. For each district, data were obtained from one
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county in which the study occurred and in another county
selected randomly.
The Georgia DHR supplied the following data for the
selected counties: 1) the number of patients treated and
the percentage of patients who achieved controlled blood
pressure; 2) the costs of prescription drugs, postage, and
overhead; and 3) the cost of clinical services. To estimate
clinical costs per patient, we divided the annual total costs
per county by the total number of SHAPP patients treated
in each county. We assumed that the costs identified in the
selected counties were representative of the overall per-
patient costs in each health district.
The percentage of SHAPP patients treated with pre-
scription drugs was calculated by dividing the number of
patients who received any prescription drug in each dis-
trict by the number of patients in that district. The cost per
patient for prescribed drugs was calculated by dividing the
total annual prescription drug cost in each district by the
number of patients who received any drugs. Postage costs
per patient were calculated by dividing aggregate postage
costs (to mail prescriptions to SHAPP clinics) in each dis-
trict by the number of patients in each district.
Government overhead costs for SHAPP statewide were
provided by Georgia DHR for all SHAPP patients
statewide. These costs included personnel costs (salary and
benefits) and operating costs (pharmacy and clinical). This
total cost was converted to a per-person cost by dividing it
by the number of statewide SHAPP participants, and this
cost was then applied to patients in the respective districts.
SHAPP’s annual treatment cost per patient was calculat-
ed as the sum of per-patient clinical, prescription drug,
postage, and state overhead costs.
Comparison treatment costs
For comparison purposes, estimates of the number of
patients receiving treatment and the expected level of
hypertension control for patients who receive treatment
were obtained from reported national hypertension trends
derived from the third National Health and Nutrition
Examination Survey (NHANES III) (1). Because no exact
definition exists of what treatment in the private sector
entails, we assumed that such treatment was based on the
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7) guidelines, which would be com-
parable to SHAPP treatment (3). Therefore, we defined
usual care (for people who received treatment) as the aver-
age number of annual hypertension visits for SHAPP par-
ticipants (3.71 visits), combined with the same drug treat-
ment used by SHAPP patients in District 1.
The cost of usual care was estimated by multiplying the
average number of annual hypertension visits for SHAPP
participants (3.71 visits) by the Centers for Medicaid and
Medicare Services (CMS) Medicare reimbursement rate for
office visits ($80). To this we added the average per-person
drug costs observed in the SHAPP program. We assumed
no postage or state overhead costs for usual care. Because
not all patients with hypertension receive care, we then
multiplied this total per-patient cost for those who receive
care by the estimated proportion of patients who receive
any treatment (1). Table 1 presents a comparison of costs
and outcomes for patients in District 1 and District 2 and
for patients nationally.
We noted that prescription costs per patient were higher
in District 1. On further examination of the data, we found
that even though drug costs per type of prescription were
consistent statewide, District 1 used a greater quantity of
some drugs such as hydrocortothiazide, hydralazine, and
fosinopril. In contrast, per-patient clinical services were
more costly in District 2. Although most reported proce-
dure codes are the same in both districts, the data show
that some differences in service use exist. Overall, patients
in District 2 used more clinical services such as phone con-
sultation, preventive counseling, and laboratory test
reviews than patients in District 1. Also, the cost per pro-
cedure was routinely more expensive per unit of service in
District 2 than District 1. Focus groups with patients and
key informant interviews with administrators and staff in
both districts indicated that each SHAPP district offers the
same basic set of services. The observed differences in costs
between the two districts studied, however, indicate that
SHAPP implementation varies among districts; the tech-
nology used to capture and report cost and usage data may
vary as well.
Outcomes
We defined SHAPP effectiveness as the proportion of
patients with controlled blood pressure in each health dis-
trict, based on statistics from Georgia DHR annual
reports. Using these reported levels of blood pressure con-
trol, we then estimated the number of adverse events
expected in each health district based on the results of a
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published statistical model by Flack and colleagues (12).
The model was designed to estimate the annual probabili-
ty of hemorrhagic and ischemic stroke and heart disease
for individuals in three categories of blood pressure treat-
ment and control: 1) treated and controlled, 2) treated but
uncontrolled, and 3) untreated and uncontrolled (12). We
used this model to make estimates because time and fund-
ing limitations prevented us from observing adverse out-
comes or measuring associated costs directly. The Flack
study was selected for modeling purposes because it pro-
vided the most recent and comprehensive information
related to the SHAPP study. It examined the effect of inad-
equate blood pressure control on selected cardiovascular
disease outcomes and analyzed related costs for the U.S.
population with hypertension. In addition, the study devel-
oped a sophisticated model, provided incidence rates for
cardiovascular disease morbidity and mortality, and inte-
grated hypertension statistics from NHANES III and cost
estimates for stroke, congestive heart failure, and myocar-
dial infarction (12). NHANES III was conducted in
1999–2000; the published results were the most recent
available at the time of the Flack study.
We calculated the cost-effectiveness of SHAPP by com-
paring two other treatment possibilities — no treatment
and usual care — based on expected adverse outcomes
observed in the absence of a public program. The propor-
tions of the U.S. population with treated and controlled,
treated but uncontrolled, and untreated and uncontrolled
blood pressure were taken from a published analysis of
NHANES III surveillance data for 1999–2000 (1) (Table 2).
The probability of hemorrhagic stroke based on treatment
and control of blood pressure was taken from the published
results of a randomized controlled study of more than
45,000 participants in the Netherlands that provided pop-
ulation-based estimates; the goal of this study was to
examine the outcomes (i.e., number of strokes) associated
with insufficient treatment of hypertension (11). The prob-
ability of ischemic stroke was derived by applying the ratio
of ischemic strokes to hemorrhagic strokes identified in the
2001 Medical Expenditure Panel Study (MEPS) (16) to the
probabilities of hemorrhagic stoke identified in the
Netherlands study. The probability of kidney failure was
derived from two separate studies of hypertension-related
adverse events, the second of which studied hypertension-
related renal failure (13,17). Rates of heart disease and the
costs of each expected adverse event were obtained from
the Flack simulation model of cardiovascular disease asso-
ciated with uncontrolled blood pressure (12). Costs for
stroke and heart attack reported in the Flack study repre-
sent estimates of inpatient and outpatient costs during 1
year after the adverse event. Inpatient costs represent the
majority of costs and were obtained from the National
Inpatient Profile (a database derived from the National
Hospital Discharge Survey); outpatient costs included typ-
ical follow-up care, medications, laboratory tests, and office
visits (12). The cost of treating congestive heart failure was
obtained from the economic burden-of-illness estimates
from the American Heart Association (12).
Results
The SHAPP program achieved blood pressure control
rates of 68.1% in District 1 and 59.7% in District 2 (Table
1). The average control rate for all SHAPP districts is 54%,
with a range of 41% to 68% (data not shown). The compar-
ative national control rate was 53% for patients in treat-
ment, translating to a 31% control rate for all patients
nationally when accounting for individuals who do not
seek treatment (Table 2) (1). Annual preventive treatment
costs per patient were $132.36 in District 1 and $260.39 in
District 2. The average number of clinical services between
the two districts and the same pharmaceutical care that
was used in District 1 would cost $322 per patient in the
private sector. However, because only 58% of patients with
hypertension nationally receive preventive treatment, the
estimated national annual per-patient cost for treated
patients with hypertension ($187.04) was between the
annual costs per patient in the two districts.
Because SHAPP achieved higher blood pressure control
rates and offered care to all patients who were eligible and
sought treatment, SHAPP patients in both districts were
expected to experience lower rates of hemorrhagic stroke,
ischemic stroke, heart disease, and kidney failure com-
pared with both other treatment scenarios (no care and
usual care) (Table 3). Patients in District 1 were expected
to experience roughly 10 fewer expected adverse events
than if they had received no treatment and seven fewer
than if they had received usual care. Patients in District 2
were expected to experience roughly 30 fewer expected
adverse events than if they had received no treatment and
21 fewer than if they had received usual care.
The differences in the number of expected adverse out-
comes translated into substantial differences in costs
among the three scenarios. Total expected annual costs for
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SHAPP patients, including both preventive treatment and
care related to expected adverse outcomes in District 1,
were estimated at $289,617 for no treatment, $323,095 for
usual care, and $209,800 for SHAPP treatment. In District
2, costs were estimated at $870,451 for no treatment,
$971,070 for usual care, and $848,254 for SHAPP treat-
ment (Table 4). In each county, SHAPP was the least
expensive of the three treatment scenarios. Total expected
costs for SHAPP patients in District 1 were 27.5% below the
costs of no treatment, and 35.1% below the costs of treat-
ment offered only through the private sector. In District 2,
where treatment costs were higher, total costs of SHAPP
were 2.6% below the costs of no treatment and 12.7% below
the costs of treatment offered only through the private sec-
tor. When examining both districts to provide a more glob-
al picture of SHAPP, we found that implementation of the
SHAPP program resulted in both lower costs and greater
potential health benefits than either of the alternative
treatment scenarios. SHAPP saved costs and provided
greater health benefits when compared with both no treat-
ment for hypertension and usual care (Table 5).
SHAPP costs differed between the two health districts.
Table 1 shows that although District 1 reported lower costs
per patient overall than District 2, District 1 prescribed
medications to a greater proportion (94%) of clients than
District 2 (63%). District 1 also paid more for medications
($49.56 per patient) than District 2 ($15.19 per patient). In
contrast, District 1 used fewer clinical services per patient
(8.0) than District 2 (12.6) and paid less for the services.
Discussion
SHAPP is an education and direct service program that
appears to save costs for the state of Georgia. SHAPP
resulted in lower costs and better health outcomes than
either no treatment or treatment offered at the average
level expected nationally. For the two districts examined,
SHAPP was found to be preferable to the other two options
because it resulted in both better blood pressure control
levels (which are expected to translate into fewer adverse
health events), lower treatment costs for those who receive
treatment, and lower overall costs per eligible patient.
These results were supported by blood pressure control
rates of 68.1% in District 1 and 59.7% in District 2. Both
these rates exceed the national average control rate for
patients in treatment (53%) and for all patients with
hypertension, including the untreated (31%). The average
control rate for SHAPP during this study period was 54%.
Although the SHAPP districts that were evaluated had
higher control rates, we believe that these rates can be
reached by other districts.
SHAPP still saved costs when expected adverse out-
comes were considered, although the cost savings covered
a narrow range of direct medical costs. Had we included
lost productivity and deaths associated with the expected
adverse events that SHAPP prevented, the benefits of
SHAPP compared with the benefits of other treatment
options would likely appear even more substantial. This
cost analysis was one element of an initial program evalu-
ation that also included both medical record review and
focus groups with patients as well as key informant inter-
views with administrative and clinical staff. This evalua-
tion also identified important components that contribute
to high blood pressure control rates: intense patient moni-
toring, follow-up, access to medication, and counseling. 
This study is limited by several factors. First, because of
funding and time constraints, only two districts were
examined. Also, districts with high blood pressure control
rates were analyzed because the primary objectives of the
study were to examine program components that con-
tributed to successful blood pressure outcomes and to com-
municate results to other hypertension programs. Limited
information on adverse events among SHAPP patients
was available, and no actual outcomes in the population
were observed. All expected adverse events were inferred
from the medical literature using the probability of
adverse events based on different levels of blood pressure
control. The conclusions are accurate to the extent that
populations observed in other studies reflect the charac-
teristics of the SHAPP population. Populations in other
studies used for this analysis vary in their similarity to the
SHAPP population. When selecting parameter values for
the model, we balanced demographic similarity with data
completeness, fit of the parameter, and size of the study.
For example, Klungel et al used data from a study of more
than 45,000 individuals and thus had the statistical power
to observe differences that would be missed by other small-
er studies. In addition, Klungel et al examined precisely
the measure we sought: the probability of stroke given
uncontrolled and controlled hypertension.
Second, medical costs for private-sector care were esti-
mated based on service usage observed in SHAPP. Thus,
the results may overestimate the effectiveness of the
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SHAPP statewide. A better approach for estimation would
include direct observation of the costs of preventive servic-
es in the private sector and comparison of private-sector
costs with SHAPP costs. In addition, a more comprehen-
sive approach would be to examine SHAPP on a statewide
basis, including districts with varying rates of success.
Future models should use more complicated simulations
that vary the number of assumptions.
On the other hand, the costs assigned in this study were
conservative, particularly prescription costs. A more pre-
cise estimate of private-sector costs would likely make
SHAPP appear more cost-effective because SHAPP pro-
vides protocol-driven, evidence-based treatment, and most
treatment is provided by nurses instead of physicians. We
have no way of knowing how SHAPP patients would use
services in the absence of the program, so we must rely on
hypothetical scenarios for comparison. Finally, because we
used data from two higher-performing SHAPP districts,
this study identified the upper range of program effective-
ness. However, hypertension control rates representing all
SHAPP districts (ranging from 41% to 68%) exceed the
rates of hypertension control observed nationally in
NHANES (31%).
This study evaluated the costs and benefits of SHAPP
based on observed data on program costs and outcomes and
on similar data published in the medical literature trans-
lated into adverse events in other settings. These findings
show that SHAPP treatment is more cost-effective than no
treatment or treatment offered only through the private
sector. Compared with the two other plausible scenarios
tested, SHAPP resulted in the lowest medical costs and the
best patient health outcomes. Given these conclusions, we
hypothesize that SHAPP’s full coverage of patients is
preferable to both no patient care and the average amount
of care expected nationally both in terms of costs and health
outcomes. It is important to view these results in the 
context of the growing expense of health care and the
importance of implementing prevention programs that are
successful and reduce costs.
However, it is also important to keep the limitations of
the study in mind. Promising practices at the state level
too often are left unexplored because of a lack of funding or
an inability to acquire data. This evaluation provides pre-
liminary evidence of the effectiveness of an intervention
based on the Chronic Care Model to control hypertension
among disadvantaged individuals, but limited time and
resources led to a simple simulation that used data from a
limited number of locations and relied on several assump-
tions. We recommend more extensive and more formal
evaluations of SHAPP and other hypertension interven-
tions based on the Chronic Care Model to better under-
stand how these interventions work and to more precisely
measure program success.
Because SHAPP costs are borne by the taxpayer and at
least some portion of private care is paid for by consumers,
it is important to consider who would bear the costs of car-
ing for adverse outcomes if SHAPP were eliminated. First,
because patients in SHAPP are indigent, they would be far
more likely to receive no care than the average amount of
care received nationally if the program were eliminated.
This analysis suggests that such a change would result in
a substantial increase of expected adverse events and
deaths. Because most SHAPP patients do not carry private
insurance, the higher cost of caring for these adverse
events would likely fall on already overextended public
hospitals, the state Medicaid program, and federally fund-
ed indigent care programs. Thus, the elimination of
SHAPP would likely result in higher costs for both the
state and federal governments, making it financially pru-
dent for Georgia to maintain the program. The higher costs
of not providing care due to the occurrence of adverse
events far exceed the costs of treating hypertension and
preventing those events. More importantly, SHAPP pro-
vides access to vital services for indigent Georgians to
address this critical, life-threatening health issue.
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Tables
Table 1. Costs and Outcomes for Patients in Districts 1 and 2 of the Georgia Stroke and Heart Attack Prevention Program
Compared With National Values
Percentage of patients with controlled blood pressure 68.1 59.7 31a
No. of clinical services per patient per year 8.0 12.6 Not estimated
Clinical cost per patient treated, $ per year 79.58 244.59 296.80
Percentage of treated patients using prescription drugs 94 63 78b
Prescription costs per patient prescribed, $ per year 49.56 15.19 32.73b
Postage cost per patient, $ per year 0.44 0.10 0
State overhead costs per patient, $ per year 5.61 5.61 0
Percentage of patients receiving preventive treatment 100 100 58
Annual preventive treatment cost per patient, $ per year 132.36 260.39 187.04a
aWe assumed that only 58% of patients with hypertension receive preventive treatment in the absence of a public program, as suggested by the literature
(1), and estimated that the hypertension control rate for patients receiving treatment was 53% (1). 
bWe assumed that these values were equal to the average of the SHAPP districts.
Table 2. Differences in Annual Expected Rates of Adverse Health Events Among Americans With Treated and Controlled,
Treated but Uncontrolled, and Untreated Hypertension
Rates among Americans with hypertensiona 31.0 27.4 41.6 Not applicable
Adverse event
Hemorrhagic strokeb 0.13 0.16 0.28 26,000
Ischemic strokec 0.54 0.66 1.12 26,000
Heart diseased 0.70 0.90 1.20 12,300
Kidney failuree 0.22 0.27 0.77 2,822
aSource: Hajjar and Kotchen (1). 
bSources: Klungel et al (11) and Flack et al (12). 
cWe assumed that the ratio of hemorrhagic stroke to ischemic stroke is 1:4 (16). 
dSource: Flack et al (12). 
eSources: Tierney et al (13), Perneger et al (17), Smith et al (18).
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District 1 District 2
Cost or Outcome (N = 543) (N = 1632) National (Usual Care)
Category of Hypertension Care
Treated Treated but Cost Per Event
and Controlled, % Uncontrolled, % Untreated, % (in 2001 Dollars)
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Table 3. Expected Number of Annual Adverse Health Events Associated With District 1 and District 2 Patients in the Georgia
Stroke and Heart Attack Prevention Program (SHAPP) Under Three Treatment Scenarios
Hemorrhagic stroke 1.52 1.09 0.69 4.57 3.28 2.12
Ischemic stroke 6.08 4.43 2.76 18.28 13.32 8.46
Heart disease 6.52 5.23 3.66 19.58 15.73 11.26
Kidney failure 4.19 4.80 1.12 12.59 14.44 3.42
Total 18.31 15.56 8.23 55.02 46.77 25.27
Table 4. Annual Estimated Costs of Expected Adverse Health Events Associated With District 1 and District 2 Patients in the
Georgia Stroke and Heart Attack Prevention Program (SHAPP) Under Three Treatment Scenarios
Adverse event
Hemorrhagic strokea 39,530 28,391 17,953 118,810 85,330 55,009
Ischemic strokea 158,122 115,203 71,815 475,238 346,245 220,037
Heart diseasea 80,146 64,385 45,002 240,883 193,510 138,577
Kidney failureb 11,818 13,554 3,157 35,520 40,736 9,675
Total costs, $
Total cost of adverse events 289,617 221,532 137,929 870,451 665,821 423,297
Total cost of preventive treatment 0 101,563 71,871 0 305,249 424,957
Total combined costs (event plus 289,617 323,095 209,800 870,451 971,070 848,254
preventive treatment)
aData from Flack et al (12). 
bData from Smith et al (18).
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District 1 District 2
(N = 543) (N = 1632)
Treatment Scenario Treatment Scenario
National National
Adverse Event None (Usual Care) SHAPP None (Usual Care) SHAPP
District 1 District 2
(N = 543) (N = 1632)
Treatment Scenario Treatment Scenario
Adverse Events National National
and Total Costs None (Usual Care) SHAPP None (Usual Care) SHAPP
Table 5. Annual Expected Adverse Health Events and Estimated Costs Associated With Patients in the Georgia Stroke and
Heart Attack Prevention Program (SHAPP) Under Three Treatment Scenarios
Total no. of adverse events 73.32 62.33 33.50
Incremental benefit compared with no preventive treatment Not applicable 11.00 39.82
Total cost of adverse events, $ 1,160,068 887,353 561,227
Total cost of preventive treatment, $ 0 406,812 496,828
Combined costs (event plus preventive treatment), $ 1,160,068 1,294,165 1,058,055
Total combined costs per patient, $ 534 595 486
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District 1 and District 2 Combined 
(N = 2175)
Treatment Scenario
National
Event or Cost None (Usual Care) SHAPP
